Head Office
The Ropewalks
Newton Street
SK11 6QJ, UK

+44 (0)3332224269

Bioscript Science LLC
103 Carnegie Center
Suite 300
Princeton, NJ 08540 6235 

+1 (609) 664 9973

Contact form

Patient involvement in HTA processes: Anticipating the impact of the JCA

Is your HTA strategy ready for the JCA?

The European Union’s Joint Clinical Assessment (JCA), launching in 2025, is poised to revolutionise health technology assessment (HTA) by placing greater emphasis on patient perspectives and experiences. This shift presents both challenges and opportunities for pharmaceutical companies as they navigate drug approvals in an evolving landscape. Our in-depth white paper explores the far-reaching implications of the JCA, providing actionable insights to help you adapt your HTA strategy, meaningfully engage with patients, and ultimately ensure your products are aligned with the heightened focus on patient centricity.


Download the white paper below:



A breadth of capabilities

Our global capabilities cover strategic planning, scientific communications, data insights, market access consultancy and regulatory medical writing. This cross-discipline approach means we can help you navigate across internal departments, external stakeholder groups and international markets at pace.

Find out more


Start your journey with us
Get in touch